Evotec (OTCMKTS:EVTCY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, Deutsche Bank raised shares of Evotec from a “hold” rating to a “buy” rating in a research report on Wednesday, August 21st.

EVTCY stock traded up $1.55 during midday trading on Friday, reaching $45.20. 100 shares of the company were exchanged, compared to its average volume of 708. The business has a 50-day moving average price of $48.51 and a two-hundred day moving average price of $50.99. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of 34.24 and a beta of 1.28. Evotec has a one year low of $35.57 and a one year high of $59.50. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.36 and a quick ratio of 1.33.

Evotec (OTCMKTS:EVTCY) last announced its earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.26). The business had revenue of $116.02 million during the quarter. Evotec had a net margin of 19.00% and a return on equity of 15.24%. As a group, analysts anticipate that Evotec will post 0.52 earnings per share for the current fiscal year.

About Evotec

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.

Further Reading: Penny Stocks

Get a free copy of the Zacks research report on Evotec (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.